Bristol Myers Squibb Company $BMY Shares Sold by Wells Trecaso Financial Group LLC

Wells Trecaso Financial Group LLC lowered its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 53.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 18,889 shares of the biopharmaceutical company’s stock after selling 21,602 shares during the quarter. Wells Trecaso Financial Group LLC’s holdings in Bristol Myers Squibb were worth $852,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in shares of Bristol Myers Squibb by 1.8% during the second quarter. Vanguard Group Inc. now owns 194,925,206 shares of the biopharmaceutical company’s stock worth $9,023,088,000 after buying an additional 3,522,202 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Bristol Myers Squibb by 16.8% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 70,802,680 shares of the biopharmaceutical company’s stock valued at $3,277,456,000 after acquiring an additional 10,195,775 shares in the last quarter. Geode Capital Management LLC raised its holdings in Bristol Myers Squibb by 1.6% in the 2nd quarter. Geode Capital Management LLC now owns 46,176,690 shares of the biopharmaceutical company’s stock valued at $2,132,976,000 after acquiring an additional 723,459 shares during the last quarter. Norges Bank purchased a new position in Bristol Myers Squibb in the 2nd quarter worth approximately $1,554,154,000. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Bristol Myers Squibb by 1.3% during the 2nd quarter. Ameriprise Financial Inc. now owns 32,579,618 shares of the biopharmaceutical company’s stock worth $1,508,099,000 after purchasing an additional 432,158 shares during the last quarter. 76.41% of the stock is owned by institutional investors and hedge funds.

Bristol Myers Squibb Price Performance

Shares of BMY opened at $61.21 on Friday. The firm has a 50-day simple moving average of $54.08 and a two-hundred day simple moving average of $48.92. The company has a debt-to-equity ratio of 2.39, a current ratio of 1.27 and a quick ratio of 1.17. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $63.33. The stock has a market cap of $124.61 billion, a PE ratio of 20.74, a P/E/G ratio of 0.18 and a beta of 0.29.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. The company had revenue of $12.50 billion during the quarter, compared to analyst estimates of $12.24 billion. During the same quarter last year, the business posted $1.67 EPS. The firm’s revenue for the quarter was up 1.3% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, analysts forecast that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, February 2nd. Investors of record on Friday, January 2nd were issued a dividend of $0.63 per share. This is a positive change from Bristol Myers Squibb’s previous quarterly dividend of $0.62. The ex-dividend date was Friday, January 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 85.14%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 17th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $60.00 target price on shares of Bristol Myers Squibb in a research note on Friday. Truist Financial set a $65.00 price target on shares of Bristol Myers Squibb in a research report on Wednesday, December 3rd. Leerink Partners raised their price objective on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research report on Tuesday, January 13th. Finally, Guggenheim reaffirmed a “buy” rating and set a $72.00 target price on shares of Bristol Myers Squibb in a research note on Friday. Eight equities research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb currently has an average rating of “Hold” and an average price target of $58.73.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Company raised FY‑2026 guidance (EPS range and revenue guidance above street estimates), signaling management expects stronger full‑year performance. Bristol Myers forecasts upbeat 2026
• Positive Sentiment: Q4 revenue beat consensus and the Growth Portfolio (newer products, including immuno‑oncology) expanded meaningfully, helping offset declines in older drugs — a primary driver of the stock reaction. Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
• Positive Sentiment: Management (CEO) highlighted what it calls the strongest pipeline in a decade and emphasized new growth engines (R&D and manufacturing deals), which supports longer‑term upside expectations. Bristol Myers Squibb CEO: Richest product pipeline we’ve had in the last decade
• Neutral Sentiment: Company published the earnings presentation and full call transcript — useful for modeling specifics (guidance ranges, product-level trends, and expected timing of catalysts). Q4 Results – Earnings Call Presentation Q4 Earnings Call Transcript
• Negative Sentiment: Reported non‑GAAP EPS dynamics were mixed: some headlines framed an EPS miss versus certain consensus figures (while other outlets reported beats vs different estimates), creating short‑term noise around profitability trends. Company press release: Q4 and full-year results
• Negative Sentiment: Legacy drug revenue continues to decline; investors should watch whether growth products can sustainably replace that revenue and how pricing moves (e.g., Eliquis cuts) play out operationally. WSJ: Revenue ticks up on immuno‑oncology growth

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.